Zinc and Vitamin E: study protocols
30 study groups took Zinc together with Vitamin E. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Zinc
30 study groups in 25 studies say how much Zinc participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 37% of 30 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg or less | 2 |
| 5 mg to 10 mg | 5 |
| 10 mg to 25 mg | 11 |
| 25 mg to 50 mg | 3 |
| 50 mg to 100 mg | 9 |
Dose per serving from research: Vitamin E
18 study groups in 17 studies say how much Vitamin E participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 33% of 18 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mg to 2.5 mg | 2 |
| 2.5 mg to 5 mg | 1 |
| 5 mg to 10 mg | 4 |
| 10 mg to 25 mg | 6 |
| 25 mg to 50 mg | 5 |
Commonly used together
30 of 30 study groups took Zinc and Vitamin E with something else. Shown: what 3 or more different studies gave. The 10 most common of 16.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin C | 30 |
| Copper | 17 |
| Beta-Carotene | 15 |
| Selenium | 14 |
| Vitamin A | 11 |
| Iron | 10 |
| Iodine | 8 |
| Vitamin D | 8 |
| Vitamin B12 | 7 |
| Vitamin B6 | 7 |
30 study groups
| Study | ||||
|---|---|---|---|---|
| Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis 2016 · combination of antioxidants and zinc · Adults aged 55 years and older with age-related macular degeneration; eyes with advanced disease at baseline and participants with no AMD in both eyes were excluded | 80 mg | 400 IU | 2409 days | — |
| Megadose vitamins in bladder cancer: a double-blind clinical trial 1994 · megadose vitamins arm · Patients with biopsy-confirmed transitional cell carcinoma of the bladder receiving BCG immunotherapy | 90 mg | — | — | 35 |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 80 mg | 400 IU | 8 years | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 30 mg | 10 mg | — | — |
| Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13 2004 · antioxidants plus zinc · Adults aged 55–81 years with AMD categories 2–4 and AREDS ocular eligibility | 80 mg | 400 IU | 339 weeks | — |
| The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals 2004 · antioxidant supplement group · French women aged 35–60 and men aged 45–60 in the general population | 20 mg | 30 mg | 2739 days | — |
| Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels? 2005 · daily antioxidant supplementation · French adults: women aged 35–60 years and men aged 45–60 years | 20 mg | 30 mg | 2739 days | — |
| Antioxidant supplementation increases the risk of skin cancers in women but not in men 2007 · antioxidant group · French adult women and men in a general-population primary-prevention trial | 20 mg | 30 mg | 2738 days | — |
| Effect of micronutrient supplementation on diarrhoeal disease among stunted children in rural South Africa 2009 · multiple micronutrients · children aged 6–24 months; three cohorts: HIV-infected children, HIV-uninfected children born to HIV-infected mothers, and HIV-uninfected children born to HIV-uninfected mothers | 10 mg | 6 mg | 548 days | — |
| Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 2013 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration (AREDS categories 1–4) | 80 mg | 400 IU | 339 weeks | — |